PET brain scan of Alzheimer's patient (photo credit: Eli Lilly)
July 17, 2023 10:14 AM EDTUpdated 01:51 PM
R&D
Pharma

Up­dat­ed: Eli Lil­ly ex­pects FDA de­ci­sion on Alzheimer’s drug by end of year as it un­veils full PhI­II da­ta

Lei Lei Wu

News Reporter

Eli Lil­ly said Mon­day morn­ing that it has sub­mit­ted an ap­pli­ca­tion for its ex­per­i­men­tal Alzheimer’s drug do­nanemab to the FDA, and ex­pects a de­ci­sion by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times